WO2003029215A1 - 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders - Google Patents

4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders Download PDF

Info

Publication number
WO2003029215A1
WO2003029215A1 PCT/SE2002/001804 SE0201804W WO03029215A1 WO 2003029215 A1 WO2003029215 A1 WO 2003029215A1 SE 0201804 W SE0201804 W SE 0201804W WO 03029215 A1 WO03029215 A1 WO 03029215A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
piperidin
carbamoylphenyl
ylidene
benzamide
Prior art date
Application number
PCT/SE2002/001804
Other languages
French (fr)
Inventor
William Brown
Christopher Walpole
Zhongyong Wei
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002460168A priority Critical patent/CA2460168A1/en
Priority to EP02775640A priority patent/EP1440060A1/en
Priority to HU0401915A priority patent/HUP0401915A2/en
Priority to MXPA04003056A priority patent/MXPA04003056A/en
Priority to KR10-2004-7004780A priority patent/KR20040039469A/en
Priority to BR0212959-0A priority patent/BR0212959A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to IL16088902A priority patent/IL160889A0/en
Priority to US10/491,263 priority patent/US7205317B2/en
Priority to JP2003532465A priority patent/JP2005505583A/en
Publication of WO2003029215A1 publication Critical patent/WO2003029215A1/en
Priority to IS7203A priority patent/IS7203A/en
Priority to NO20041964A priority patent/NO20041964L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds.
  • the novel compounds are useful in therapy, and in particular for the treatment of pain.
  • the ⁇ receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the ⁇ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the ⁇ receptor have also been shown to possess immunomodulatory activities.
  • the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side- effect profile over current ⁇ agonists, as well as having improved systemic efficacy.
  • novel compounds according to the present invention are defined by the formula I
  • R is selected from any one of
  • each R phenyl ring and R heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents independently selected from straight and branched C]-Cg alkyl, NO2, CF3, C i -C ⁇ alkoxy, chloro, fluoro, bromo, and iodo.
  • the substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems.
  • novel compounds according to the present invention are defined by the formula
  • R is selected from any one of
  • the preferred substituents are independently selected from any one of CF3, methyl, iodo, bromo, fluoro and chloro.
  • novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.
  • Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti- tumour agents and anti viral agents.
  • Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).
  • PET positron emission tomography
  • Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety, urinary incontinence, various mental illnesses, cough, lung oedema, various gastro- intestinal disorders, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
  • Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care.
  • Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
  • a further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.
  • a further aspect of the present invention is intermediates of the general formula II
  • PG is a urethane protecting group such as Boc or CBZ, or a benzyl or substituted benzyl protecting group, such as 2,4-dimethoxybenzyl.
  • novel compounds according to the present invention may be administered orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, inrracerebroventricularly and by injection into the joints.
  • a preferred route of administration is orally, intravenously or intramuscularly.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low- melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low- melting wax, cocoa butter, and the like. Salts include, but are not limited to, pharmaceutically acceptable salts.
  • Examples of pharmaceutically acceptable salts within the scope of the present invention include: acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glucaptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabarnine, hydrobromide, hydrochloride, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate
  • Preferred pharmaceutically acceptable salts are the hydrochJorides, sulfates and bitartrates.
  • hydrochloride and sulfate salts are particularly preferred.
  • composition is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it.
  • a carrier which is thus in association with it.
  • cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid from compositions include solutions, suspensions, and emulsions.
  • Sterile water or water- propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical composition is in unit dosage form. In such fonn, the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage fonn can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • Human 293 S cells expressing cloned human ⁇ , ⁇ , and K receptors and neomycin resistance were grown in suspension at 37°C and 5% CO 2 in shaker flasks containing calcium- free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 ⁇ g/ml geneticin.
  • mice and rat brains were weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride, added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).
  • ice-cold PBS containing 2.5mM EDTA, pH 7.4
  • the brains were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride, added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).
  • Cells were pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec. The suspension was spun at 1000 g (max) for 10 min at 4 °C. The supernatant was saved on ice and the pellets resuspended and spun as before. The supernatants from both spins were combined and spun at 46,000 g (max) for 30 min. The pellets were resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again.
  • lysis buffer 50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol
  • Membranes were thawed at 37 °C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A-7888), pH 7.4, which was stored at 4°C after filtration through a 0.22 m filter, and to which had been freshly added 5 ⁇ g/ml aprotinin, 10 ⁇ M bestatin, 10 ⁇ M diprotin A, no DTT). Aliquots of 100 ⁇ l were added to iced 12x75 mm polypropylene tubes containing 100 ⁇ l of the appropriate radioligand and 100 ⁇ l of test compound at various concentrations.
  • binding buffer 50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A-7888), pH 7.4
  • binding buffer 50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A
  • Total (TB) and nonspecific (NS) .binding were detemiined in the absence and presence of 10 ⁇ M naloxone respectively.
  • the tubes were vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum- filtered and washed with about 12 ml tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM MgCt) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine.
  • the radioactivity (dpm) retained on the filters was measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid.
  • the filtration is over 96-place PEL soaked unifilters, which were washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h.
  • the filter plates were counted in a TopCount (Packard) after adding 50 ⁇ l MS -20 scintillation fluid well.
  • the agonist activity of the compounds is measured by deterrriining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled.
  • GTP[ ⁇ ] 35 S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate GTP[ ⁇ ] 35 S binding in these membranes.
  • the EC 50 and E r>ax values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors.
  • the specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB.
  • Values of IC50 and Hill coefficient (nj-i) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GrapliPad Prism, SigmaPlot, or ReceptorFit.
  • Values of K j were calculated from the Cheng- Prussoff equation.
  • Mean ⁇ S.E.M. values of IC50, K, and n ⁇ were reported for ligands tested in at least three displacement curves. Biological data are tabulated on the following pages in Table 1.
  • Table 1 Biological data.
  • Radioligand Kg values were dete ⁇ nined by perfoirning the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K ⁇ (up to 10 times if amounts of radioligand required are feasible).
  • radioligand binding was expressed as pmole/mg membrane protein. Values of Kg and B max from individual experiments were obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one- site model.
  • Rats were placed in Plexiglas cages on top of a wire mesh bottom which allowed access to the paw, and were left to habituate for 10- 15 min. The area tested was the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw was touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, 111, USA).
  • the von Frey hair was applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, 5 and held for approximately 6-8 seconds. A positive response was noted if the paw was sharply withdrawn. Flinching immediately upon removal of the hair was also considered a positive response. Ambulation was considered an ambiguous response, and in such cases the stimulus was repeated.
  • the animals were tested on postoperative day 1 for the FCA-treated group.
  • the 50%) l o withdrawal threshold was determined using the up-down method of Dixon (1980). Testing was started with the 2.04 g hair, in the middle of the series. Stimuli were always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen.
  • Optimal threshold calculation by this method requires 6 responses 15 in the immediate vicinity of the 50% threshold, and counting of these 6 responses began when the first change in response occurred, e.g. the threshold was first crossed.
  • Rats were injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varied depending upon the nature of the test compound.
  • Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.
  • a complete and typical Writhing reflex is considered only when the following elements are l o present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of both paws is observable.
  • compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1- 1 OO ⁇ mol/kg.
  • Acetic acid 120 ⁇ L of Acetic Acid is added to 19.88 ml of distilled water in 15 order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.
  • the compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.)) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing.
  • Intraventricularly (i.c.v.) or intrathecally (it.) a volume of 5 ⁇ L is administered.
  • the AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the 5 average mice body weight) immediately prior to testing.
  • mice The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box” cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

Abstract

Compounds of general formula (I) wherein R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl and triazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C¿1?-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on thephenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, inparticular in the management of pain.

Description

4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
Field of the Invention
The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain.
Background of the Invention
The δ receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the δ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the δ receptor have also been shown to possess immunomodulatory activities.
The identification of at least three different populations of opioid receptors (μ, δ and K) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.
With few exceptions, cun'ently available selective opioid δ ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic δ-agonist is SNC80 (Bilsky E.J. et al, Journal of Pharmacology and Experimental Therapeutics, 273(1), pp. 359-366 (1995)). There is however still a need for selective δ-agonists having not only improved selectivity, but also an improved side- effect profile.
Thus, the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side- effect profile over current μ agonists, as well as having improved systemic efficacy.
Analgesics that have been identified and exist in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that preferred δ agonist compounds, described within the prior art, show significant convulsive effects when administered systemically. We have now found that certain compounds not specifically disclosed by, but included within the scope of WO 98/28275, exhibit suφrisingly improved δ -agonist properties and in vivo potency.
Outline of the invention
The novel compounds according to the present invention are defined by the formula I
wherein
Figure imgf000004_0001
1 . R is selected from any one of
(i) phenyl;
Figure imgf000004_0002
(ii) pyridinyl
(iii) thienyl
(iv) furanyl
Figure imgf000004_0003
N
(v) imidazolyl \\
(vi) triazolyl
(vii) pyrrolyl ; and
(vϋi) thiazoly]
Figure imgf000005_0001
l o where each R phenyl ring and R heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents independently selected from straight and branched C]-Cg alkyl, NO2, CF3, C i -Cβ alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems.
Particularly, novel compounds according to the present invention are defined by the formula
15
.1 . wherein R is selected from any one of
Figure imgf000005_0002
(i) phenyl
(ii) pyridinyl
Figure imgf000005_0003
0
(iii) thienyl and
Figure imgf000005_0004
(iv) furanyl
Figure imgf000006_0001
Within the scope of the invention are also salts and enantiomers of the compounds of the formula I.
When the phenyl ring and the heteroaromatic ring(s) are substituted, the preferred substituents are independently selected from any one of CF3, methyl, iodo, bromo, fluoro and chloro.
The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.
Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti- tumour agents and anti viral agents.
Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).
Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety, urinary incontinence, various mental illnesses, cough, lung oedema, various gastro- intestinal disorders, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
Also within the scope of the invention is the use of any of the compounds according to the fo iula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.
A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.
A further aspect of the present invention is intermediates of the general formula II
Figure imgf000007_0001
wherein PG is a urethane protecting group such as Boc or CBZ, or a benzyl or substituted benzyl protecting group, such as 2,4-dimethoxybenzyl.
Methods of preparation
EXAMPLES
The invention will now be described in more detail by the following Schemes and Examples, which are not to be construed as limiting the invention.
Figure imgf000008_0001
5g: R'= 3-pyridine 5h: R1= 2-pyrrole 5i: R,= 4-pyridine 5j : R1= 4-imidazole
Scheme 1 : Synthetic Route to Compounds of the Present invention
N,N-DiethyI-4-[N-Boc-piperidin-4-yUdene(3-carboxyphenyl)-methyl]-benzamide (2a).
A mixture of 4- [bromo-(4-diethylcarbamoyl-phenyl)-methylene]-piperiα,ine- 1 -carboxylic acid tert-butyl ester (la, 451 mg, 1.0 mmol), 3-carboxyphenyl boronic acid (330 mg, 2.0 mmol), 2M Na2CO3 (3 mL), and tetrakis(triphenyl phosphine) palladιum(O) (25 mg) in toluene (degassed, 10 mL) and ethanol (degassed, 10 mL) was refluxed at 90°C for 4 hrs under N2. The reaction mixture was then quenched with aqueous NFLC1 after cooling down to 0 °C, and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with brine, dried over MgSO4> and evaporated to give a crude product, which was purified by flash silica gel column to provide the desired compound 2a (345 mg, 70 %): Η NMR (CDCfe) δ 1.15 (3 H, br m, CFJ3CH2-), 1.23 (3 H, br m, CH3CH2-), 1.47 (9 H, s, C(CH3)3), 2.31 (2 H, m, piperidine CH-), 2.35 (2 H, m, piperidine CH-), 3.30 (2 H, br m, CH3CH2N-), 3.48 (4 H, m, piperidine CH-), 3.54 (2 H, br m, CH3CH2N-), 7.14 (2 H, d, J = 8.0 Hz, ArH), 7.24 (1 H, m, ArH), 7.33 (2 H, d, J = 8.0 Hz, ArH), 7.42 (1 H, t, J - 7.6 Hz, ArH), 7.86 (1 H, s, ArH), 7.97 (1 H, d, J = 7.6 Hz, ArH). IR (NaCl) 2976, 1718, 1691, 1598, 1430, 1233, 1166 cm"1. N,N-Diethyl-4-fl-(benzyI-piperidin-4-ylidene-(3-carboxyphenyl)-methyl]-benzamide (2b).
Method as for 2a using lb (441 mg, 1.0 mmol) and 3-carboxyphenyl boronic acid (330 mg, 2.0 mmol) provided 2b (325 mg, 67 %): Η NMR (CDCI3) δ 1.1 1 (3 H, br m, CH3CH2-), 1.22 (3 H, br m, CH3CH2-), 2.63 (4 H, m, piperidine CH-), 2.90 (4 H, m, piperidine CH-), 3.26 (2 H, br m, CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 4.00 (2 H, s, CH2N-), 7.1 1 (2 H, d, J = 8.0 Hz, ArH), 7.16 (1H, m, ArH), 7.30 (6 H, m, ArH), 7.42 (2 H, m, ArH), 7.84 (1 H, s, ArH), 7.96 (l H, d, J = 7.6 Hz, ArH).
N,N-Diethyl-4-[l-benzylpiperidin-4-ylidene(3-carbamoyIphenyl)-methyl]-benzamide (3b).
241 mg (0.5 mmol) of N,N-diethyl-4-[piperidin-4-ylidene(3-carboxyphenyl)-methyl]- benzamide (2b), 780 mg (1.5 mmol) of PyBOP, and 200 mg (1.5 mmol) of HOBt were dissolved in 4 mL DMF. 0.58 mL (4 mmol) of DIPEA and 50 mg (10.0 mmol) of NHLtCl were added successively. After stirred for 0.5 h at room temperature, the reaction mixture was quenched with water and ethyl ether. The white precipitates were collected as the desired product (3b, 152 mg, 63 %): Η NMR (CDCk) δ 1.10 (3 H, br m, CH3CH2-), 1.21 (3 H, br m, CH3CH2-), 2.62 (4 H, m, piperidine CH-), 2.89 (4 H, m, piperidine CH-), 3.26 (2 H, br m, CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 4.00 (2 H, s, CH2N-), 7.11 (2 H, d, J = 8.0 Hz, ArH), 7.16 (1H, m, ArH), 7.30 (6 H, m, ArH), 7.42 (2 H, m, ArH), 7.84 (1 H, s, ArH), 7.96 (1 H, d, J = 7.6 Hz, ArH); .4na/.Cfl/c<//or C3 iH35N3θ2 6.0 HCl: C, 53.16 %; H, 5.90 %; Found: C, 53.07 %; H, 5.54 %.
N,N-Diethyl-4-[piperidin-4-ylidene(3-carbamoyIphenyl)-methyl]-benzamide (4).
Method as for 3b using 2a (150 mg, 0.30 mmol) provided 3a (105 mg, 70 %): Η NMR (CDCI3) δ 1.14 (3 H, br m, CH3CH2-), 1.22 (3 H, br m, CH3CH2-), 1.46 (9 H, s, C(CH3)3), 2.28 (2 H, m, piperidine CH-), 2.33 (2 H, m, piperidine CH-), 3.30 (2 H, br m, CH3CH2N- 3.46 (4 H, m, piperidine CH-), 3.55 (2 H, br m, CH3CH2N-), 7.13 (2 H, d, J = 8.0 Hz, ArH), 7.30 (3 H, m, ArH), 7.39 (1 H, t, J = 7.6 Hz, ArH), 7.61 (1 H, s, ArH), 7.68 (1 H, d, J = 7.6 Hz, ArH).
The above product (3a) was treated with 4.0 M HC1 in dioxane (10 mL) at room temperature for 4 h. After evaporation, the residue was dissolved in H2O (10 mL) and impurities were extracted with ethyl acetate (2 x 20 mL). The aqueous phase was basified with NHjOH and extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with brine, dried over MgSO4 and evaporated to give 4 in quantitative yield: Η NMR (CDCfe) δ 1.15 (3 H, br m, CH3CH2-), 1.23 (3 H, br m, CH3CH2-), 1.90 (2 H, br, NH2), 2.31 (2 H, m, piperidine CH-), 2.34 (2 H, m, piperidine CH-), 2.92 (4 H, m, piperidine CH-), 3.32 (2 H, br m, CH3CH2N-), 3.55 (2 H, br m, CH3CH2N-), 7.13 (2 H, d, J = 8.0 Hz, ArH), 7.30 (3 H, m, ArH), 7.38 (1 H, t, J = 7.6 Hz, ArH), 7.58 (1 H, s, ArH), 7.66 (1 H, d, J = 7.6 Hz, ArH). IR (NaCl) 3307, 2973, 1668, 1615, 1435, 1383, 1289 cm ' Anal.Calcd.for C24H29N3O2 2.8 HC1: C, 58.40 %; H, 6.49 %; Found: C, 58.46 %; H, 6.57 %.
N,N-Diethyl-4-[l-(2-thiophene)methyl-piperidin-4-ylidene-(3-carbamoylphenyI)-methyl]- benzamide (5a).
To a mixture of N,N-ώethyl-4-[piperidin-4-ylidene(3-carbamoylphenyl)-methyl]- benzamide (4, 196 mg, 0.5 mmol), 2-thiophenecarboxaldehyde (1 12 mg, 1.0 mmol), acetic acid (0.1 mL) in MeOH (10 mL) was added NaBH3(CN) (200 mg) in portions. The reaction mixture was stirred for 4 h at room temperature, and then quenched with aqueous NH4CI, extracted with CH2C12 (3 x 50 mL). The combined organic phases were washed with brine, dried over MgSO4, and evaporated to give a crude product, which was purified by flash silica gel column to give the desired product (5a, 216 mg, 89 %). 'H NMR (CDCi) 6 1.13 (3 H, br m, CH3CH2-), 1.22 (3 H, br m, CH3CH2-), 2.36 (2 H, m, piperidine CH-), 2.42 (2 H, m, piperidine CH-), 2.54 (4 H, m, piperidine CH-), 3.26 (2 H, br m, CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 3.76 (2 H, s, CH2N-), 5.60 (1 H, br, NH), 6.06 (1 H, br, NH), 6.91 (1 H, s, ArH), 6.94 (1 H, m, ArH), 7.12 (2 H, d, J = 8.0 Hz, ArH), 7.26 (1 H, m, ArH), 7.30 (3 H, m, ArH), 7.37 (1 H, t, J = 7.6 Hz, ArH), 7.56 (1 H, s, ArH), 7.64 (1 H, d, J = 7.6 Hz, ArH). IR (NaCl) 3352, 2973, 1668, 1614, 1434, 1290 cm Anal.Calcd.for C29H33N3O2S 2.3 HC1: C, 60.95 %; H, 6.23 %; Found: C, 60.96 %; H, 6.42 %. N,N-Diethyl-4-[l-(2-furfui7l-piperidin-4-ylidene-(3-carbamoyIphcnyl)-methyl]-benzamide
(5b).
Method as for 5a using 4 (196 mg, 0.5 mmol) and 2-furaldehyde (96 mg, 1.0 mmol) provided 5b (158 mg, 67 %): Η NMR (CD ) δ 1.12 (3 H, br m, CH3CH2-), 1.22 (3 H, br m, CH3CH2-), 2.41 (4 H, m, piperidine CH-), 2.83 (4 H, m, piperidine CH-), 3.27 (2 H, br m,
CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 3.88 (2 H, s, CH.2N-), 6.18 (1 H, br, NH), 6.35 (1 H, m, ArH), 6.42 (1 H, m, ArH), 6.86 (1 H, m, NH), 7.12 (2 H, d, J - 8.0 Hz, ArH), 7.27 (3 H, m, ArH), 7.32 (1 H, m, ArH), 7.41 (1 H, s, ArH), 7.61 (1 H, s, ArH), 7.69 (1 H, d, J = 7.6 Hz, ArH); Anal.Calcd.for C29H33N3O3 3.0 HCl: C, 59.95 %; H, 6.25 %; Found: C, 59.68 %; H, 5.98 %.
N,N-Diethyl-4-[l-(3-furfuryl-piperidin-4-yhdene-(3-carbamoylphenyl)-methyl]-benzamide
(5c).
Method as for 5a using 4 (196 mg, 0.5 mmol) and 3-furaldehyde (96 mg, 1.0 mmol) provided 5c (143 mg, 61 %): Η NMR (CDCI3) δ 1.13 (3 H, br m, CH3CH2-), 1.25 (3 H, br m, CH3CH2-), 2.42 (4 H, m, piperidine CH-), 2.70 (4 H, m, piperidine CH-), 3.26 (2 H, br m,
CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 3.62 (2 H, s, CH2N-), 5.80 (1 H, br, NH), 6.42 (1 H, br, NH), 6.46 (1 H, s, ArH), 7.12 (2 H, d, J = 8.0 Hz, ArH), 7.28 (3 H, m, ArH), 7.36 (1 H, t, J = 7.6 Hz, ArH), 7.42 (2 H, m, ArH), 7.59 (1 H, s, ArH), 7.66 (1 H, d, J = 7.6 Hz, ArH); Anal.Calcd.for C29H33N3O3 3.1 HCl: C, 59.58 %; H, 6.22 %; Found: C, 59.44 %; H, 6.45 %.
N,N-Diethyl-4-[l-(2-pyridine)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl)- benzamide (5d).
Method as for 5a using 4 (196 mg, 0.5 mmol) and 2-pyridinecarboxaldehyde (107 mg, 1.0 mmol) provided 5d (35 mg, 15 %): Η NMR (CDCfe) δ 1.13 (3 H, br m, CH3CH2-), 1.24 (3 H, br m, CH3CH2-), 2.38 (2 H, m, piperidine CH-), 2.42 (2 H, m, piperidine CH-), 2.56 (4 H, m, piperidine CH-), 3.26 (2 H, br m, CH3CH.2N-), 3.54 (2 H, br m, CH3CH2N-), 3.68 (2 H, s, CH2N-), 5.64 (1 H, br, NH), 6.12 (1 H, br, NH), 7.14 (3 H, m, ArH), 7.31 (3 H, m, ArH), 7.35 (1 H, m, ArH), 7.38 (1 H, m, ArH), 7.56 (1 H, s, ArH), 7.65 (2 H, m, ArH), 8.58 (1 H, m, ArH).
N,N-Diethyl-4-[l-(3-thiophene)methyI-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]- benzamide (5e).
Method as for 5a using 4 (196 mg, 0.5 mmol) and 3-thiophenecarboxaldehyde (112 mg, 1.0 mmol) provided 5e (185 mg, 76 %): 'H NMR (CDCk) δ 1.13 (3 H, br m, CH3CH2-), 1.24 (3 H, br m, CH3CH2-), 2.46 (4 H, m, piperidine CH-), 2.84 (4 H, m, piperidine CH-), 3.26 (2 H, br m, CH3CH2N-), 3.52 (2 H, br m, CH3CH2N-), 3.91 (2 H, s, CH2N-), 5.72 (1 H, br, NH), 6.44 (1 H, br, NH), 7.13 (3 H, m, ArH), 7.26 (3 H, m, ArH), 7.36 (3 H, m, ArH), 7.61 (1 H, s, ArH), 7.68 (1 H, d, J = 7.6 Hz, ArH); Anal. Cα/α/ or C29H33N3O2S 2.5 HCl: C, 60.18 %; H, 6.18 %; Found: C, 60.16 %; H, 6.49 %.
N,N-Diethyl-4-[l-(2-thiazole)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyI]- benzamide (5f).
To a solution of N,N-diethyl-4-[piperidin-4-ylidene(3-carbamoylphenyl)-methyl]- benzamide (4, 300 mg, 0.8 mmol) in 1,2-dichloroethane (15 mL) was added 2-thiazole carboxaldehyde (94 μL, 1.1 mmol) and sodium triacetoxyborohydride (228 mg, 1.1 mmol). The reaction mixture was stirred for 20h at room temperature, and then quenched with aqueous NaHCO3. The aqueous phase was extracted with CH2CI2 (2 x 20 mL) and the combined organic phases were dried over MgSO4, filtered and evaporated. The crude product was purified by flash chromatography to give product (5f) as a yellow foam (234 mg, 63% yield).
The product was dissolved in dichloromethane (5mL) and a solution of HCl in ether (IN, 1.4 mL, 3eq.) was added. After 30 minutes the suspension was concentrated and the solid dried. Η NMR (CDC1,) δ 1.10 (3H, t, J=7Hz, CH3) ; 1.21 (3H, t, J=7Hz, CH3) ; 2.64 (4H, br s, CH2) ; 3.27-3.31 (4H, m, CH2) ; 3.48-3.53 (2H, m, CH2) ; 3.67 (2H, br s, CH2) ; 4.77 (2H, s, NCH2Ar) ; 7.27 (2H, d, J=8.5Hz, Ar-H) ; 7.33-7.37 (3H, m, Ar-H) ; 7.44 (1H, t, J=7.5Hz, Ar-H) ; 7.68- 7.69 (1H, m, Ar-H) ; 7.75-7.78 (2H, m, Ar-H) ; 7.94 (1H, d, J=3.5Hz, Ar-H). Anal. Calcdfor C28H32N4O2S x 2.5HC1: C, 58.00%; H, 6.00%; N, 9.66%; Found: C, 58.00%; H, 5.95%; N, 9.43%.
N,N-Diethyl-4-[l-(3-pyridine)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]- benzamide (5g).
Method as for 5f using 4 (176 mg, 0.45 mmol) and 3-pyridinecarboxyaldehyde (60 μL, 0.6 mmol) provided 5g (91.5 mg, 42 %): Η NMR (CDCfe) δ 1 .09 (3H, t, J=7Hz, CH3) ; 1.21 (3H, t, J=7Hz, CH3) ; 2.68-2.75 (4H, m, CH2) ; 3.26-3.28 (4H, m, CH2) ; 3.43-3.60 (4H, m, CH2) ; 4.65 (2H, s, NCH2Ar) ; 7.27 (2H, d, J=8.5Hz, Ar-H) ; 7.32-7.36 (3H, m, Ar-H) ; 7.43 (1H, t, J=8Hz, Ar-H) ; 7.70-7.71 (1H, m, Ar-H) ; 7.75-7.78 (1H, m, Ar-H) ; 8.19 (1H, dd, J=6, 8Hz, Ar-H) ; 8.88 (1H, d, J=8Hz, Ar-H) ; 8.98 (1H, d, J=6Hz, Ar-H) ; 9.21 (1H, s, Ar-H). Anal. Calcdfor C30H3 N4O2 x 3.1HC1 x 0.4H2O: C, 59.77%; H, 6.34%; N, 9.29%; Found: C, 59.70%; H, 6.36%; N, 9.17%.
N,N-Diethyl-4-[l-(2-pyrrole)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyi]- benzamide (5h).
Method as for 5f using 4 (261 mg, 0.7 mmol) and 2- pyrrol ecarboxyaldehyde (89 mg, 0.9 mmol) provided 5h (1 18.5 mg, 38 %): Η NMR (CDCt) δ 1.09 (3H, t, J=7Hz, CH3) ; 1.21 (3H, t, J=7Hz, CH3) ; 2.46-2.53 (2H, m, CH2) ; 2.65-2.77 (2H, m, CH2) ; 2.97-3.04 (2H, m, CH2) ; 3.26-3.30 (2H, m, CH2) ; 3.46-3.52 (4H, m, CH2) ; 4.30 (2H, s, NCH2Ar) ; 6.33-6.34 (1H, m, Ar-H) ; 6.85-6.86 (1H, m, Ar-H) ; 7.24-7.26 (2H, m, Ar-H) ; 7.30-7.36 (4H, m, Ar-H) ; 7.40- 7.45 (1H, m, Ar-H) ; 7.67-7.68 (1H, m, Ar-H) ; 7.75-7.77 (1H, m, Ar-H). Anal. Calcdfor C29H34N4O2 x 1.1HC1 x 1.8H2O: C, 64.13%; H, 7.18%; N, 10.32%; Found: C, 64.26%; H, 7.15%; N, 9.94%.
N,N-DiethyI-4-[l-(4-pyridine)methyI-piperidin-4-ylidene-(3-carbamoylphenyl)-methyI]- benzamide (5i).
Method as for 5f using 4 (329 mg, 0.8 mmol) and 4-pyridinecarboxyaldehyde (1 12 μL, 1.2 mmol) provided 5i (217 mg, 54 %): Η NMR (CDC13) δ 1.12 (3H, t, J=7Hz, CH3) ; 1.24 (3H, t, J=7Hz, CH3) ; 2.67-2.82 (4H, m, CH2) ; 3.22-3.34 (4H, m, CH2) ; 3.49-3.65 (4H, m, CH2) ; 4.72 (2H, s, NCH2Ar) ; 7.29 (2H, d, J=8.5Hz, Ar-H) ; 7.33-7.40 (3H, m, Ar-H) ; 7.46 (1H, t, J=8Hz, Ar-H) ; 7.72-7.73 (1H, m, Ar-H) ; 7.78-7.80 (1H, m, Ar-H) ; 8.37 (2H, d, J=7Hz, Ar-H) ; 9.00 (2H, d, J=7Hz, Ar-H).
N,N-Dicthyl-4-[l-(4-pyridine)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]- benzamide (5j).
Method as for 5f using 4 (313 mg, 0.8 mmol) and 4-imidazolecarboxyaldehyde (108 mg, 1.1 mmol) provided 5j (68.2 mg, 18 %): Η NMR (CDC1,) δ 1.12 (3H, t, J=7Hz, CH3) ; 1.23 (3H, t, J=7Hz, CH3) ; 2.63 (2H, t, J=6Hz, CH2) ; 2.68 (2H, t, J=6Hz, CH2) ; 3.26-3.36 (6H, m, CH2) ;3.54 (2H, q, J=7Hz, CH2) ; 4.45 (2H, s, NCH2Ar) ; 7.28 (2H, d, J=8Hz, Ar-H) ; 7.32-7.40 (3H, m, Ar-H) ; 7.45 (1H, t, J=8Hz, Ar-H) ; 7.66 (1H, s, Ar-H) ; 7.71 (1H, t, J=2Hz, Ar-H) ; 7.76- 7.82 (1H, m, Ar-H) ; 8.61 (1H, s, Ar-H).
Pharmaceutical compositions
The novel compounds according to the present invention may be administered orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, inrracerebroventricularly and by injection into the joints.
A preferred route of administration is orally, intravenously or intramuscularly.
The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
For preparing suppository compositions, a low- melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low- melting wax, cocoa butter, and the like. Salts include, but are not limited to, pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts within the scope of the present invention include: acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glucaptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabarnine, hydrobromide, hydrochloride, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate. Examples of pharmaceutically unacceptable salts within the scope of the present invention include: hydroiodide, perchlorate, and tetrafluoroborate .
Preferred pharmaceutically acceptable salts are the hydrochJorides, sulfates and bitartrates.
The hydrochloride and sulfate salts are particularly preferred.
The term composition is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
Liquid from compositions include solutions, suspensions, and emulsions. Sterile water or water- propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. Preferably the pharmaceutical composition is in unit dosage form. In such fonn, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage fonn can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
BIOLOGICAL EVALUATION
In vitro model
Cell culture
A. Human 293 S cells expressing cloned human μ, δ, and K receptors and neomycin resistance were grown in suspension at 37°C and 5% CO2 in shaker flasks containing calcium- free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 μg/ml geneticin.
B. Mouse and rat brains were weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride, added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).
Membrane preparation
Cells were pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec. The suspension was spun at 1000 g (max) for 10 min at 4 °C. The supernatant was saved on ice and the pellets resuspended and spun as before. The supernatants from both spins were combined and spun at 46,000 g (max) for 30 min. The pellets were resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again. The final pellets were resuspended in membrane buffer (50 mM Tris, 0.32 M sucrose, pH 7.0). Aliquots (1 ml) in polypropylene tubes were frozen in dry ice/ethanol and stored at -70 °C until use. The protein concentrations were detemiined by a modified Lowry assay with sodium dodecyl sulfate. Binding assays
Membranes were thawed at 37 °C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCfe, 1 mg ml BSA (Sigma A-7888), pH 7.4, which was stored at 4°C after filtration through a 0.22 m filter, and to which had been freshly added 5 μg/ml aprotinin, 10 μM bestatin, 10 μM diprotin A, no DTT). Aliquots of 100 μl were added to iced 12x75 mm polypropylene tubes containing 100 μl of the appropriate radioligand and 100 μl of test compound at various concentrations. Total (TB) and nonspecific (NS) .binding were detemiined in the absence and presence of 10 μM naloxone respectively. The tubes were vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum- filtered and washed with about 12 ml tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM MgCt) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine. The radioactivity (dpm) retained on the filters was measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid. If the assay is set up in 96-place deep well plates, the filtration is over 96-place PEL soaked unifilters, which were washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h. The filter plates were counted in a TopCount (Packard) after adding 50 μl MS -20 scintillation fluid well.
Functional Assays
The agonist activity of the compounds is measured by deterrriining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled. In the GTP binding assay, GTP[γ]35S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate GTP[γ]35S binding in these membranes. The EC50 and Er>ax values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors.
Data analysis
The specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB. Values of IC50 and Hill coefficient (nj-i) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GrapliPad Prism, SigmaPlot, or ReceptorFit. Values of Kj were calculated from the Cheng- Prussoff equation. Mean ± S.E.M. values of IC50, K, and nπ were reported for ligands tested in at least three displacement curves. Biological data are tabulated on the following pages in Table 1.
Table 1 : Biological data.
Figure imgf000018_0001
Figure imgf000019_0001
Receptor saturation experiments
Radioligand Kg values were deteπnined by perfoirning the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K§ (up to 10 times if amounts of radioligand required are feasible). The specific
radioligand binding was expressed as pmole/mg membrane protein. Values of Kg and Bmax from individual experiments were obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one- site model.
Determination Of Mechano-Allodynia Using Von Frey Testing
Testing was performed between 08:00 and 16:00h using the method described by Chaplan et al. (1994). Rats were placed in Plexiglas cages on top of a wire mesh bottom which allowed access to the paw, and were left to habituate for 10- 15 min. The area tested was the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw was touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, 111, USA). The von Frey hair was applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, 5 and held for approximately 6-8 seconds. A positive response was noted if the paw was sharply withdrawn. Flinching immediately upon removal of the hair was also considered a positive response. Ambulation was considered an ambiguous response, and in such cases the stimulus was repeated.
Testing Protocol
The animals were tested on postoperative day 1 for the FCA-treated group. The 50%) l o withdrawal threshold was determined using the up-down method of Dixon (1980). Testing was started with the 2.04 g hair, in the middle of the series. Stimuli were always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen. Optimal threshold calculation by this method requires 6 responses 15 in the immediate vicinity of the 50% threshold, and counting of these 6 responses began when the first change in response occurred, e.g. the threshold was first crossed. In cases where thresholds fell outside the range of stimuli, values of 15.14 (normal sensitivity) or 0.41 (maximally allodynic) were respectively assigned. The resulting pattern of positive and negative responses was tabulated using the convention, X = no withdrawal; O = withdrawal, and the 50% withdrawal threshold was 0 interpolated using the formula:
50% g threshold = 10(Xf + kδ) / 10,000
where Xf = value of the last von Frey hair used (log units); k = tabular value (from Chaplan et al. (1994)) for the pattern of positive / negative responses; and δ = mean difference between stimuli (log units). Here δ = 0.224.
5 Von Frey thresholds were converted to percent of maximum possible effect (% MPE), according to Chaplan et al. 1994. The following equation was used to compute % MPE:
Drue treated threshold (g) - allodynia threshold (g) X 100 %MPE -
Control threshold (g) - allodynia threshold (g) Administration of Test Substance
Rats were injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varied depending upon the nature of the test compound.
5 Writhing Test
Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.
A complete and typical Writhing reflex is considered only when the following elements are l o present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of both paws is observable. In this assay, compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1- 1 OOμmol/kg.
(i) Solutions preparation
Acetic acid (AcOH): 120 μL of Acetic Acid is added to 19.88 ml of distilled water in 15 order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.
Compound (drug): Each compound is prepared and dissolved in the most suitable vehicle according to standard procedures.
(ii) Solutions administration
0 The compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.)) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing. When the compound is delivered centrally: Intraventricularly (i.c.v.) or intrathecally (it.) a volume of 5 μL is administered.
The AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the 5 average mice body weight) immediately prior to testing.
(iii) Testing The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box" cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

Claims

1. A compound of the formula I
Figure imgf000023_0001
wherein
R is selected from any one of
l o (i) phenyl
(ii) pyridinyl
Figure imgf000023_0002
Figure imgf000023_0003
(iv) furanyl
0 (v) imidazolyl
(vi) triazolyl
Figure imgf000023_0004
(vii) pyrrolyl
Figure imgf000024_0001
; and
(vϋi) thiazolyl &
where each R phenyl ring and R heteroaromatic ring may independently be further substituted by 1,
2 or 3 substituents independently selected from straight and branched Cj-Cό alkyl, NO2, CF3, C\-Cβ alkoxy, chloro, fluoro, bromo, and iodo; as well as salts thereof.
- 2. A compound according to claim 1 wherein R is selected from any one of
(i) phenyl
(ϋ) pyridinyl
(iii) thienyl
(iv) furanyl
Figure imgf000024_0002
3. A compound according to claim 1, wherein each R phenyl ring and R heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents independently selected from methyl, CF3, chloro, fluoro, bromo, and iodo.
4. A compound according to claim 1, selected from any one of
N ,N- Diethyl- 4- [piperidin-4- ylidene(3- carbamoylphenyl) -methyl] - benzamide; N,N- Diethyl- 4- [ 1 -(2-thiophene)methyl-piperidin-4-ylidene-(3-cai'bairioylphenyl)-methyl]- benzamide;
N ,N - Diethyl- 4- [ 1 - (2- furfuryl- piperidin- 4- ylidene - (3 - carbamoylphenyl) - methyl] - benzamide; N ,N - Diethyl- 4- [ 1 -( 3 - furfuryl-piperidin- 4- ylidene - (3 - carbamoylphenyl) - methyl] -benzamide; N,N-Diemyl-4-[l-(2-pyriclώe)methyl-pipericlin-
N ,N - Diethyl- 4 -[ 1 -( 3 - thiophene)methyl- piperidin- 4 - ylidene -( 3 - carbamoylphenyl) - methyl] - benzamide;
N,N-Diemyl-4-[l-(2-tMazole)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]-berιzamide; N ,N - Diethyl- 4- [ 1 - (3 -pyridine)methyl- piperidin- 4-ylidene- (3- carbamoylphenyl) -methyl] - benzamide; N,N-Diethyl-4-[l-(2-pyrrole)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]-benzanιide; N,N-Diethyl-4-[l-(4-pyridine)methyl-piperidin-4-yUdene-(3-carbanιoylphenyl)-methyl]-benzamide; and N,N-Diethyl-4-[l-(4-pyridine)methyl-piperidin-4-ylidene-(3-carbamoylphenyl)-methyl]-benzamide.
5. A compound according to Claim 1 , in forni of its hydrochloride, dihydrochloride, sulfate, tartrate, ditrifluoroacetate or citrate salts.
6. A compound according to any one of claims 1-5 for use in therapy.
7. A compound according to claim 6, wherein the therapy is pain management.
8. A compound according to' claim 6, wherein the therapy is directed towards gastrointestinal disorders.
9. A compound according to claim 6, wherein the therapy is directed towards spinal injuries.
10. A compound according to claim 6, wherein the therapy is directed to disorders of the sympathetic nervous system.
11. Use of a compound according to formula I of claim 1 for the manufacture of a medicament for use in the treatment of pain.
12. Use of a compound according to fomiula I of claim 1 for the manufacture of a medicament for use in the treatment of gastrointestinal disorders.
13. Use of a compound according to formula I of claim 1 for the manufacture of a medicament for use in the treatment of spinal injuries.
14. A pharmaceutical composition comprising a compound of the formula I according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.
15. A method for the treatment of pain, whereby an effective amount of a compound of the formula I according to claim 1 is administered to a subject in need of pain management.
16. A method for the treatment of gastrointestinal disorders, whereby an effective amount of a compound of the fomiula I according to claim 1 , is administered to a subject suffering from said gastrointestinal disorder.
17. A method for the treatment of spinal injuries, whereby an effective amount of a compound of the formula I according to claim 1, is adiriinistered to a subject suffering from said spinal injury.
PCT/SE2002/001804 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders WO2003029215A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP02775640A EP1440060A1 (en) 2001-10-03 2002-10-02 4(piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
HU0401915A HUP0401915A2 (en) 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders and pharmaceutical compositions containing them
MXPA04003056A MXPA04003056A (en) 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
KR10-2004-7004780A KR20040039469A (en) 2001-10-03 2002-10-02 4[Piperidin-4-yliden-(3-Carbamoylphenyl)methyl]benzamide Derivatives and Their Use for the Treatment of Pain, Spinal Injuries or Gastrointestinal Disorders
BR0212959-0A BR0212959A (en) 2001-10-03 2002-10-02 Compound, use thereof, pharmaceutical composition, and methods for treating pain, gastrointestinal disorders and spinal injuries
CA002460168A CA2460168A1 (en) 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
IL16088902A IL160889A0 (en) 2001-10-03 2002-10-02 4 [piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
US10/491,263 US7205317B2 (en) 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylpheny)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders
JP2003532465A JP2005505583A (en) 2001-10-03 2002-10-02 4 [piperidin-4-ylidene- (3-carbamoylphenyl) methyl] benzamide derivatives and their use for the treatment of pain, spinal cord injury or gastrointestinal diseases
IS7203A IS7203A (en) 2001-10-03 2004-03-31 4 [piperidin-4-ylidene- (3-carbamoylphenyl) methyl] benzamide derivatives and their use in the treatment of pain, spinal cord or gastrointestinal disorders
NO20041964A NO20041964L (en) 2001-10-03 2004-04-27 4- [Piperidin-4-ylidene- (3-carbamoylphenyl) methyl] benzamide derivatives and their use in the treatment of pain, spinal injuries and gastrointestinal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103313-3 2001-10-03
SE0103313A SE0103313D0 (en) 2001-10-03 2001-10-03 Novel compounds

Publications (1)

Publication Number Publication Date
WO2003029215A1 true WO2003029215A1 (en) 2003-04-10

Family

ID=20285553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/001804 WO2003029215A1 (en) 2001-10-03 2002-10-02 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders

Country Status (19)

Country Link
US (1) US7205317B2 (en)
EP (1) EP1440060A1 (en)
JP (1) JP2005505583A (en)
KR (1) KR20040039469A (en)
CN (1) CN1692100A (en)
AR (1) AR036649A1 (en)
BR (1) BR0212959A (en)
CA (1) CA2460168A1 (en)
CO (1) CO5580822A2 (en)
HU (1) HUP0401915A2 (en)
IL (1) IL160889A0 (en)
IS (1) IS7203A (en)
MX (1) MXPA04003056A (en)
NO (1) NO20041964L (en)
PL (1) PL368804A1 (en)
RU (1) RU2004107854A (en)
SE (1) SE0103313D0 (en)
WO (1) WO2003029215A1 (en)
ZA (1) ZA200402514B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041800A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
WO2004101520A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists
WO2004100952A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof as opioid receptors ligands
WO2005033073A2 (en) 2003-10-01 2005-04-14 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7241764B2 (en) 2002-11-07 2007-07-10 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
US7253173B2 (en) 2002-11-07 2007-08-07 Astrazeneca Ab 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain of gastrointestinal disorders
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2198976A2 (en) 2002-11-07 2010-06-23 Abbott Laboratories Method of loading beneficial agent to a prosthesis by fluid-jet application
WO2010093799A1 (en) 2009-02-13 2010-08-19 Abbott Laboratories Method of treating vascular disease at a bifurcated vessel using a coated balloon
US7915413B2 (en) 2001-05-18 2011-03-29 Astrazeneca Ab Compounds
EP2301619A1 (en) 2004-03-19 2011-03-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
EP2399577A1 (en) 2006-09-12 2011-12-28 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
US8129393B2 (en) 2004-08-02 2012-03-06 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
WO2016099394A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Novel selective delta-opioid receptor agonists useful for the treatment of pain, anxiety and depression.
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012117A (en) * 2003-05-16 2006-02-08 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof.
EP1644373A1 (en) * 2003-06-27 2006-04-12 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028275A1 (en) * 1996-12-20 1998-07-02 Astra Pharma Inc. Novel compounds with analgesic effect
WO2001074804A1 (en) * 2000-04-04 2001-10-11 Astrazeneca Ab Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
US5683998A (en) * 1991-04-23 1997-11-04 Toray Industries, Inc. Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
SE9504661D0 (en) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
JP4754068B2 (en) 1997-12-24 2011-08-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 4- [Aryl (piperidin-4-yl)] aminobenzamides binding to δ-opioid receptor
SE0001208D0 (en) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028275A1 (en) * 1996-12-20 1998-07-02 Astra Pharma Inc. Novel compounds with analgesic effect
WO2001074804A1 (en) * 2000-04-04 2001-10-11 Astrazeneca Ab Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022074B2 (en) 2001-05-18 2011-09-20 Astrazeneca Ab 4-(phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
US7915413B2 (en) 2001-05-18 2011-03-29 Astrazeneca Ab Compounds
EP2198976A2 (en) 2002-11-07 2010-06-23 Abbott Laboratories Method of loading beneficial agent to a prosthesis by fluid-jet application
US7241764B2 (en) 2002-11-07 2007-07-10 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
US7253173B2 (en) 2002-11-07 2007-08-07 Astrazeneca Ab 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain of gastrointestinal disorders
WO2004041800A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
US7396834B2 (en) 2002-11-07 2008-07-08 Astrazeneca Ab 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
US7960389B2 (en) 2002-11-07 2011-06-14 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
WO2004101520A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists
WO2004100952A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof as opioid receptors ligands
CN100415717C (en) * 2003-05-16 2008-09-03 阿斯特拉泽尼卡公司 Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
US7338962B2 (en) 2003-10-01 2008-03-04 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7638527B2 (en) 2003-10-01 2009-12-29 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7906646B2 (en) 2003-10-01 2011-03-15 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US8071611B2 (en) 2003-10-01 2011-12-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
WO2005033073A2 (en) 2003-10-01 2005-04-14 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2301619A1 (en) 2004-03-19 2011-03-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US8129393B2 (en) 2004-08-02 2012-03-06 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
US8022060B2 (en) 2005-03-31 2011-09-20 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2399577A1 (en) 2006-09-12 2011-12-28 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
WO2010093799A1 (en) 2009-02-13 2010-08-19 Abbott Laboratories Method of treating vascular disease at a bifurcated vessel using a coated balloon
WO2016099394A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Novel selective delta-opioid receptor agonists useful for the treatment of pain, anxiety and depression.
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
US10118921B2 (en) 2014-12-19 2018-11-06 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opoid receptor agnists
AU2015363757B2 (en) * 2014-12-19 2019-11-14 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists

Also Published As

Publication number Publication date
NO20041964L (en) 2004-04-27
SE0103313D0 (en) 2001-10-03
MXPA04003056A (en) 2004-07-05
IS7203A (en) 2004-03-31
IL160889A0 (en) 2004-08-31
CO5580822A2 (en) 2005-11-30
KR20040039469A (en) 2004-05-10
US20050020629A1 (en) 2005-01-27
JP2005505583A (en) 2005-02-24
RU2004107854A (en) 2005-09-10
BR0212959A (en) 2004-10-13
US7205317B2 (en) 2007-04-17
AR036649A1 (en) 2004-09-22
PL368804A1 (en) 2005-04-04
EP1440060A1 (en) 2004-07-28
CN1692100A (en) 2005-11-02
ZA200402514B (en) 2005-01-24
HUP0401915A2 (en) 2005-01-28
CA2460168A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US7915413B2 (en) Compounds
EP1282616B1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
US7205317B2 (en) 4[piperidin-4-yliden-(3-carbamoylpheny)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders
AU2002305994A1 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
EP1242410B1 (en) Novel compounds
EP1278740B1 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
EP1286986B1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
EP1395575B1 (en) 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP1395574B1 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
US20040152731A1 (en) 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002341487A1 (en) 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
AU2002305986A1 (en) 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002305985A1 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2004-500465

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2460168

Country of ref document: CA

Ref document number: 2002341487

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 531685

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 160889

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 772/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/02514

Country of ref document: ZA

Ref document number: 200402514

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 04030712

Country of ref document: CO

Ref document number: PA/A/2004/003056

Country of ref document: MX

Ref document number: 1020047004780

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028195825

Country of ref document: CN

Ref document number: 2003532465

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002775640

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002775640

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10491263

Country of ref document: US